GAIN THERAPEUTICS, INC (GANX) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$4.65M*; Operating income -$4.68M; Depreciation and amortization $27.17K*.
- 2026-03-31: Basis Reported; EBITDA -$5.33M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$4.44M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$4.76M*; Operating income -$4.79M; Depreciation and amortization $22.82K*.
Complete source-backed ebitda history.
- Available history
- 2020-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$4.65M* | -$4.68M | $27.17K* | (m) | (m) | (m) | -$4.68M* | (m) | $2.14M | (m) | $104.07K |
|---|
| 2026-03-31 | Reported | -$5.33M | (m) | (m) | (m) | (m) | (m) | -$4.73M | (m) | $2.76M | (m) | $183.07K |
|---|
| 2025-12-31 | Reported | -$4.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$4.76M* | -$4.79M | $22.82K* | (m) | (m) | (m) | -$4.93M* | (m) | $2.85M | (m) | $549.29K |
|---|
| 2025-06-30 | Reported | -$5.07M* | -$5.09M | $22.33K* | (m) | (m) | (m) | -$5.10M* | (m) | $2.76M | (m) | $141.21K |
|---|
| 2025-03-31 | Reported | -$4.35M | (m) | (m) | (m) | (m) | (m) | -$3.82M | (m) | $2.26M | (m) | $100.51K |
|---|
| 2024-12-31 | Reported | -$3.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$4.44M* | -$4.46M | $21.64K* | (m) | (m) | (m) | -$6.08M* | (m) | $2.62M | (m) | $10.99K |
|---|
| 2024-06-30 | Reported | -$8.16M* | -$8.18M | $20.59K* | (m) | (m) | (m) | -$5.76M* | (m) | $4.44M | (m) | $1.21K |
|---|
| 2024-03-31 | Reported | -$4.36M | (m) | (m) | (m) | (m) | (m) | -$3.59M | (m) | $2.51M | (m) | $19.87K |
|---|
| 2023-12-31 | Reported | -$4.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$4.86M* | -$4.89M | $20.51K* | $0.00* | (m) | (m) | -$3.97M* | (m) | $2.37M | (m) | $21.46K |
|---|
| 2023-06-30 | Reported | -$7.71M* | -$7.73M | $20.24K* | $0.00* | (m) | (m) | -$5.02M* | (m) | $3.99M | (m) | $26.59K |
|---|
| 2023-03-31 | Reported | -$5.21M | (m) | (m) | (m) | -9442.81% | (m) | -$4.22M | (m) | $2.79M | (m) | $16.73K |
|---|
| 2022-12-31 | Reported | -$4.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$4.73M* | -$4.75M | $17.83K* | $0.00* | (m) | $57.18K* | -$3.29M* | (m) | $1.96M | (m) | $4.05K |
|---|
| 2022-06-30 | Reported | -$5.16M* | -$5.18M | $20.02K* | $95.10K | -5421.93%* | $44.55K* | -$5.05M* | (m) | $2.58M | (m) | $9.15K |
|---|
| 2022-03-31 | Reported | -$3.28M | (m) | (m) | (m) | -8738.53% | $7.83K | -$2.45M | (m) | $1.56M | (m) | $1.68K |
|---|
| 2021-12-31 | Reported | -$3.2M | (m) | (m) | (m) | -8813.68% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$4.63M* | -$4.64M | $4.13K* | $15.97K | -29001.25%* | $32.12K* | -$2.19M* | (m) | $2.48M | (m) | $5.11K |
|---|
| 2021-06-30 | Reported | -$3.51M* | -$3.51M | $2.16K* | $81.62K | -4303.52%* | $22.50K* | -$3.22M* | (m) | $1.79M | (m) | $3.66K |
|---|
| 2021-03-31 | Reported | -$2.46M | (m) | (m) | (m) | -46754.83% | $28.49K | -$2.81M | (m) | $1.42M | (m) | $3.48K |
|---|
| 2020-12-31 | Reported | -$1.61M | (m) | (m) | (m) | -17647.46% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$816.71K* | -$819.09K | $2.38K* | (m) | (m) | $1.42K* | -$755.02K* | (m) | $427.46K | (m) | $885.00 |
|---|
| 2020-06-30 | Reported | -$530.19K* | -$532.47K | $2.28K* | (m) | (m) | -$38.00* | -$424.19K* | (m) | $438.87K | (m) | $4.52K |
|---|
| 2020-03-31 | Reported | -$510,159.00 | (m) | (m) | (m) | -7645.12% | $4.90K | -$752.82K | (m) | $417.26K | (m) | $1.35K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$18.62M | (m) | (m) | (m) | (m) | (m) | -$18.47M | (m) | $10.21M | (m) | $861.12K |
|---|
| 2024-12-31 | Reported | -$20.27M | (m) | (m) | (m) | (m) | (m) | -$18.87M | (m) | $10.79M | (m) | $536.82K |
|---|
| 2023-12-31 | Reported | -$22.17M | (m) | (m) | (m) | -40176.79% | (m) | -$18.87M | (m) | $11.52M | (m) | $79.28K |
|---|
| 2022-12-31 | Reported | -$17.71M | (m) | (m) | (m) | -13354.10% | (m) | -$14.69M | (m) | $8.38M | (m) | $92.98K |
|---|
| 2021-12-31 | Reported | -$13.81M | (m) | (m) | (m) | -10312.03% | $94.21K | -$12.37M | (m) | $7.16M | (m) | $4.01K |
|---|
| 2020-12-31 | Reported | -$3.47M | (m) | (m) | (m) | -12014.32% | $20.83K | -$3.24M | (m) | $2.26M | (m) | $5.39K |
|---|